Last reviewed · How we verify
NCT05199909
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Phase 2 trial testing zanubrutinib in Antiphospholipid Syndrome in 10 participants. Currently enrolling.
31 December 2023
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 25 January 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 June 2025 |
| Sites | 2 locations across China |
Drugs / interventions tested
- zanubrutinib (ZANUBRUTINIB) — full drug profile →
Conditions studied
- Antiphospholipid Syndrome — all drugs for Antiphospholipid Syndrome →
- Thrombocytopenia — all drugs for Thrombocytopenia →
- Treatment — all drugs for Treatment →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
18 and older, any sex, with Antiphospholipid Syndrome or Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.
Robak E, Robak T. · · 2022 · cited 45× · PMID 35628931 · DOI 10.3390/jcm11102807 -
An update on the biologics for the treatment of antiphospholipid syndrome.
Yun Z, Duan L, Liu X, Cai Q, et al · · 2023 · cited 15× · PMID 37275894 · DOI 10.3389/fimmu.2023.1145145 -
Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies.
Urra M, Lyons S, Teodosiu CG, Burwick R, et al · · 2024 · cited 10× · PMID 39156177 · DOI 10.1016/j.ekir.2024.05.016 -
Antiphospholipid Syndrome: An Antibody-Mediated Disease With Emerging Therapeutic Opportunities.
Newman TG, Knight JS. · · 2025 · cited 4× · PMID 40386969 · DOI 10.1002/art.43258 -
A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia.
Ding B, Li M, Liu L, Song X, et al · · 2025 · cited 4× · PMID 39973148 · DOI 10.1002/cnr2.70152
Verify or expand the search:
- PubMed search for NCT05199909
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of zanubrutinib
Trials testing the same drug.
- NCT06646666 — ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and AS · Phase 2 · not yet recruiting
- NCT06695013 — Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL · Phase 2 · recruiting
- NCT05290337 — ZR-CHOP in DLBCL With Specific Gene Abnormality · Phase 2 · unknown
Other recruiting trials for Antiphospholipid Syndrome
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07236762 — An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
- NCT07236801 — Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases · Phase 1 · recruiting
- NCT07163338 — Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) · NA · recruiting
- NCT06828042 — Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases · Phase 1, PHASE2 · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05199909 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 24 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05199909.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing